Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Beam Therapeutics and keeping the price target at $75.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Whitney Ijem has given his Buy rating due to a combination of factors, including Beam Therapeutics’ steady first-quarter 2026 update following previously released positive Phase 1/2 results for BEAM-302 in alpha-1 antitrypsin deficiency. The company has secured FDA agreement on a biomarker-driven accelerated approval strategy and plans to begin enrolling an expanded, potentially pivotal cohort of AATD patients in the second half of 2026, which could meaningfully de-risk the program.
In addition, Risto-cel’s Phase 1/2 data were recently published in the New England Journal of Medicine, and a biologics license application could be filed as soon as year-end, adding a nearer-term regulatory catalyst. With the remainder of the pipeline progressing as planned, a solid cash position of about $1.2 billion supporting a multi-year runway, and no change to his 12‑month price objective of $75, Ijem reiterates a constructive long-term outlook and maintains his Buy recommendation.
In another report released on May 8, Evercore ISI also maintained a Buy rating on the stock with a $45.00 price target.